Cresset expands its Board with the appointment of David Newble as Non-Executive Director
Cambridge, UK – 23 March 2021 – Cresset, innovative provider of computational solutions and services for small molecule drug discovery ...
Cambridge, UK – 15th June 2016 – Cresset, innovative provider of software and contract research services for small molecule discovery and design, is pleased to announce partnership with BioMolTech for the exclusive global distribution and support of BioMolTech’s Lead Finder docking software.
Lead Finder is a software solution for virtual screening of candidate molecules and quantitative evaluation of interactions between protein and ligand molecules through docking. Lead Finder ranks ligands by their predicted biological activity, determines 3D structures of protein-ligand complexes and estimates the energy of ligand binding. Lead Finder’s docking algorithm enables fast processing of large collections of compounds to guide the development of focused libraries with high enrichment of active compounds.
Lead Finder satisfies the needs of computational chemists and medicinal chemists involved in the discovery process, pharmacologists and toxicologists involved in the modeling and evaluation of ADMET properties in silico, and biochemists and enzymologists working on enzyme specificity and rational enzyme design. Lead Finder can be used to predict free energy of protein-ligand binding with high accuracy and prepare protein structures for independent docking experiments.
“We are delighted to be representing BioMolTech worldwide,” says Dr Rob Scoffin, CEO at Cresset. “They have an excellent scientific reputation and their products support a broad range of applications in many life science areas. We will offer Lead Finder alongside our existing software range and be integrating it into our upcoming structure-based design application.”
“BioMolTech have chosen Cresset as their distributor because we believe that Cresset is a scientifically competent, ambitious and reliable partner for representing our software worldwide” says Val Kulkov, CEO at BioMolTech. “Docking of small molecules to protein structures and evaluation of parameters of such molecular interaction is an important technique that provides valuable insight to researchers in many life science areas.”
Cresset’s software and consulting services are used by chemists from the world’s leading research organizations. Our patented methods deliver novel, realistic results for discovering, designing and optimizing the best small molecules in industry sectors including: agrochemicals, fine chemicals, flavor, fragrance, petrochemicals and pharmaceuticals.
BioMolTech aims at raising the bar in accuracy and efficiency in virtual screening and molecular docking technologies. Lead Finder, BioMolTech’s core product, is used by leading research institutions to guide the development of focused libraries with high enrichment of physiologically active compounds. We believe the continuous advancement of computer-assisted drug design technology will uncover new and innovative opportunities in life science areas.